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The phenomenon of hematogenous tumor cell dissemination in patients with solid 
tumors has been extensively explored over the last decades. Breast cancer research 
investigated at first disseminated tumor cells in the bone marrow; however, the focus 
soon moved to circulating tumor cells (CTCs) in the peripheral blood as blood is easily 
accessible without an invasive procedure. The prognostic significance of CTC presence 
has been shown in large studies both in adjuvant and metastatic setting and commercially 
available detection assays have been evaluated for monitoring in clinical trials. Beyond 
detection and enumeration of CTCs, the characterization of single tumor cells may 
enhance our knowledge on disease progression and thus optimize treatment choices.
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iNTRODUCTiON
Breast cancer (BC) is the most common cancer type in women; its mortality is mostly due to distant 
metastatic growth. The phenomenon of hematogenous spread of single tumor cells shed from the 
primary tumor was first demonstrated in nineteenth century (1, 2). Tumor cells encountered at 
secondary homing sites, such as bone marrow (BM) and peripheral blood (PB), are currently seen as 
surrogate marker for minimal residual disease (MRD) and precursors of distant metastasis. Detection 
of these cells and evaluation of their features can therefore contribute to our better understanding of 
the disease and improve therapy monitoring as well as personalized treatment options. The features 
of tumor cells and changes in the microenvironment at the homing site are the major subject of 
current translational research.
The prognostic significance of MRD in BC was first demonstrated in studies on disseminated 
tumor cells (DTCs) in BM. In 2005, a multicenter meta-analysis of BM aspirates collected from 4703 
non-metastatic BC patients at time of diagnosis confirmed that DTC presence significantly correlates 
with shorter disease-free survival (DFS) and overall survival (3). Since venipuncture is more feasible 
than BM aspiration, subsequent studies shifted their focus to the easily accessible circulating tumor 
cells (CTCs) in the PB. The following review will address the current knowledge and future clinical 
possibilities of CTC evaluation in BC.
Abbreviations: BC, breast cancer; BCSS, breast cancer-specific survival; CTC, circulating tumor cell; DDFS, distant disease-free 
survival; DFS, disease-free survival; DMFS, distant metastasis-free survival; DTC, disseminated tumor cell; EpCAM, epithelial 
cell adhesion molecule; HER2, human epidermal growth factor receptor 2; MFS, metastasis-free survival; MRD, minimal 
residual disease; OS, overall survival; PFS, progression-free survival; RT-PCR, reverse transcription polymerase chain reaction.
TABLe 1 | Presence of CTCs and clinical outcome in non-metastatic BC patients.
Reference Patients Number of 
patients
CTC 
positivity
Method Median 
follow-up 
(months)
Association 
between CTCs and 
survival
Janni et al. (16) 
pooled analysisa
Stages I–III 3173 641 (20%) CellSearch 63 DFS, DDFS, BCSS, 
OS
Rack et al. (13), 
SUCCESS trial 
Stages I–III, node-positive or high-risk node-
negative, all pts. received chemotherapy
2026 435 (21%) CellSearch 36 DFS, DDFS, BCSS, 
OS
Franken et al. (15) Stages I–III 404 76 (19%) CellSearch 48 DDFS, BCSS
Lucci et al. (23) Stages I–III 302 73 (24%) CellSearch 35 DFS, OS
Bidard et al. (14), 
REMAGUS02 trial
Neoadjuvant trial, Stages II and III, ineligible for 
breast conserving surgery at diagnosis or high-risk
95 22 (23%) CellSearch 70 DDFS, OS
Molloy et al. (24) Stages I and II 733 58 (8%) qRT-PCR (CK19, p1B, 
EGP-2, PS2, and MmGI)
91 MFS, BCSS
Ignatiadis et al. (17) Stages I–III, all pts. received adjuvant 
chemotherapy
444 181 (41%) RT-PCR (CK19) 54 DFS, OS
Kuniyoshi et al. (25) Stages I–III 167 RT-PCR (CK19, 
c-erbB-2)
n.s.
Hwang et al. (19) Stages I–IIIa 166 37 (22%) RT-PCR (CK20) 100 MFS, OS
n.s., not significant; BCSS, breast cancer-specific survival; DDFS, distant disease-free survival; DFS, disease-free survival; OS, overall survival; MFS, metastasis-free survival.
aPooled analysis including data from five centers, some previously published as Ref. (13, 14, 15, 23).
2
Banys-Paluchowski et al. Circulating Tumor Cells in Breast Cancer
Frontiers in Oncology | www.frontiersin.org December 2016 | Volume 6 | Article 255
CiRCULATiNG TUMOR CeLLS iN eARLY 
BReAST CANCeR
The metastatic cascade consists of a series of steps that enable cells 
from the primary tumor to enter blood vessels, persist in initially 
hostile homing sites, and finally extravasate into the tissue of 
secondary organs. These steps may take place over a prolonged 
period of time, sometimes decades, involving mechanisms 
known as tumor cell dormancy (4). Due to improved screening, 
the majority of BC patients presents with disease localized to the 
breast and lymph nodes without evidence of distant metastasis. 
However, after completion of surgical treatment and adequate 
adjuvant therapy, a significant proportion of patients suffer from 
a distant recurrence, suggesting that the metastatic cascade had 
already been activated long before diagnosis.
Accumulating evidence suggests that the fate of tumor cells 
detached from the primary tumor is highly influenced not only 
by their own properties but also by microenvironment and 
immune system. In the blood stream and later in BM and distant 
organs, these rare cells are exposed to immune response of the 
host. It is widely accepted that a significant proportion of CTCs 
dies leaving only a small subpopulation capable of persistence, 
in a process generally referred to as “metastatic inefficiency” 
(5). Due to the rapid clearance of CTCs from the blood stream 
mediated by macrophages, monocytes, neutrophils, and natural 
killer cells, MRD is under continuous survival pressure to develop 
mechanisms enabling immune escape (6). Indeed, CTCs have 
been shown to overexpress proteins inhibiting the phagocytic 
activity of immune cells and downregulate major histocompat-
ibility class I antigen expression (7–10). It has also been suggested 
that CTCs are able to stimulate the formation of premetastatic 
niche in secondary organs. In this context, a number of possible 
mechanisms have been proposed. Through expression of vascular 
signal proteins, CTCs can attract VEGFR-expressing hematopo-
etic stem cells that influence fibroblasts at the homing site, thus 
creating a favorable microenvironment for future metastatic 
growth (11). In an animal BC model, tumor cells were shown to 
induce production of chemokine ligands, especially CCL17 and 
CCL22, at secondary sites, leading to chemotaxis of both tumor 
and immune cells. A better knowledge of interactions between 
CTCs, the immune system and microenvironment could provide 
us with new therapeutic targets (12).
Prognostic Significance of  
CTCs in early BC
Non-metastatic BC patients in whom tumor cells spread into 
the blood stream, i.e., who present with CTCs in their PB, are 
more likely to relapse in the course of disease (Table 1). To date, 
the largest clinical trial on the prognostic relevance of CTCs in 
early BC was launched by the German SUCCESS study group 
(EUDRA-CT No. 2005-000490-21, NCT02181101). Briefly, 
blood samples from over 2000 average-to-high-risk non-
metastatic BC patients before chemotherapy and nearly 1500 
patients after chemotherapy were examined (13). Women with 
detectable CTCs before chemotherapy had significantly worse 
DFS and overall survival. In this trial, the relationship between 
CTC numbers and survival was evaluated in order to determine 
the optimal cutoff (no CTCs vs. ≥1; 0–1 vs. ≥2; 0–4 vs. ≥5 CTCs 
in 30 ml blood). For all cutoffs, a statistically significant impact 
on survival was shown. Women with five and more CTCs had 
highest risk for relapse. So far, the results from the SUCCESS 
trial were reported after a median follow-up of 36  months. 
Smaller trials with longer follow-up demonstrated the associa-
tion between CTC presence and clinical outcome as well (14, 15). 
In a multicenter pooled analysis, Janni et  al. confirmed CTC 
presence in early BC patients as an independent predictor of 
shorter disease-free, overall, BC-specific, and distant DFS (16). 
In the multivariate analysis, for all four survival endpoints alike, 
grading, tumor stage, nodal stage, hormone receptor status, and 
HER2 status were additional significant independent prognostic 
factors, while histologic type, menopausal status, neoadjuvant 
chemotherapy, and adjuvant chemotherapy were not significantly 
TABLe 2 | Presence of persistent CTCs and clinical outcome in non-metastatic BC patients.
Reference Patient collective Number 
of  
patients
CTC  
positivity
Method Median 
follow-up 
(months)
Association 
between 
CTCs and 
survival
Association between CTCs 
and pathological response 
of the primary tumor to 
neoadjuvant therapy
Rack et al. (13), 
SUCCESS trial
Stages I–III, node-positive or high risk node-
negative; blood sample taken after adjuvant 
chemotherapy
1493 330 (22%) CellSearch 36 DFS, OS –
Riethdorf 
et al. (34), 
GeparQuattro trial
High-risk non-metastatic BC after 
neoadjuvant chemotherapy
207 22 (11%) CellSearch – n.d. No
Kasimir-Bauer 
et al. (35)
Neoadjuvant trial, Stages II and III, ineligible 
for breast conserving surgery at diagnosis 
or high-risk; blood and BM samples taken 
before and after neoadjuvant chemotherapy
133 11 (8%) AdnaTest 52 No No
Hall et al. (36) Triple-negative early BC after neoadjuvant 
chemotherapy
57 17 (30%) CellSearch 30 RFS, OS No
Bidard et al. (14), 
Pierga et al. (37) 
REMAGUS02 trial
Neoadjuvant trial, Stages II and III, ineligible 
for breast conserving surgery at diagnosis 
or high-risk; blood sample taken after 
neoadjuvant chemotherapy
85 15 (18%) CellSearch 70 No No
DFS, disease-free survival; OS, overall survival; RFS, relapse-free survival.
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associated with disease recurrence or survival. Beyond that, the 
analysis added important new data on the prognostic value of 
CTCs in various BC subgroups. Most importantly, CTC pres-
ence did not significantly influence clinical outcome in low-risk 
patients with small node-negative tumors, suggesting that early-
stage BCs could be treated successfully, independently of the 
presence of MRD in the blood. In contrast, the strong prognostic 
value of CTCs in high-risk patients underlines the future poten-
tial of CTCs to drive treatment decisions in this patient group. 
Furthermore, Janni et al. evaluated CTC detection in different 
molecular subgroups. Hypothetically, tumor cell dissemination 
patterns may differ according to the biological features of the 
disease. Indeed, CTC presence predicted survival in patients 
with tumors of the luminal subtype (i.e., hormone receptor-
positive, including luminal B HER2-positive subtype) and with 
triple-negative tumors, but not in patients with HER2-positive, 
hormone receptor-negative tumors (16). Contrary to these 
results, Ignatiadis et al. found in a smaller study no association 
between CTC presence and prognosis in patients with luminal 
tumors, while CTC status was highly predictive of survival in 
the triple-negative and HER2-subtype (17, 18). Similar findings 
were reported by others (19–21). One aspect that needs to be 
taken into account is a relatively short follow-up of the available 
studies; so far, none of the abovementioned trials reported a 
follow-up longer than 100 months. Especially in case of hormone 
receptor-positive BC, this might be insufficient to fully assess 
the clinical relevance of CTC presence as patients with luminal 
tumors are more at risk for a late relapse compared to those with 
more aggressive tumor subtypes (22).
The ability to assess tumor subtypes has been one of the mile 
stones toward personalized oncological treatment. In this con-
text, considerable efforts have been undertaken to characterize 
the phenotype of CTCs and explore potential clinical applications 
beyond mere enumeration of tumor cells. It has been shown that 
expression profiles of CTCs do not correlate with the subtype 
of the corresponding primary tumor (26). However, while the 
presence of CTCs has been confirmed as an important predictor 
of worse survival in large trials, evidence regarding prognostic 
relevance of specific subtypes of CTCs in early BC is scarce. 
Wulfing et al. assessed the HER2 status of CTCs in a small cohort 
of 35 stages I–III BC patients and reported a significant associa-
tion between positive HER2 status and shorter DFS and overall 
survival (27).
The relationship between DTCs in BM and CTCs in PB has 
been explored in a number of studies. While both DTCs and CTCs 
have been shown to predict clinical outcome with level I evidence 
(3, 16), only a few studies assessed both markers in patients with 
primary BC. The correlation between CTC and DTC positivity 
seems weak, ranging from 55 to 76%, depending on the patient 
population and the method used (28–31). Which “homing site” 
is better suited for survival prediction remains unclear; while sev-
eral studies found a stronger correlation between DTC presence 
and clinical outcome, others provided results in favor of CTCs. 
The major advantage of blood-based detection is the simplicity of 
blood sampling in comparison to BM biopsy. Since the procedure 
is non-invasive, serial measurements are possible.
CTCs as a Therapy Monitoring  
Tool in early BC
Breast cancer patients in whom MRD in the BM persist beyond 
adjuvant chemotherapy are more likely to be diagnosed with a 
subsequent relapse (32). Evidence from CTC-based clinical tri-
als showed that persistence of CTCs in the blood is associated 
with worse clinical outcome as well (Table 2). The SUCCESS 
trial demonstrated that CTC persistence correlates with shorter 
recurrence-free and overall survival (13). When both prechem-
otherapy and postchemotherapy CTC status was considered, 
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the 36-month OS and DFS were higher in patients who were 
CTC-negative at both time points compared to those CTC-
positive before and after chemotherapy (OS: 97.6 vs. 92.8%; 
DFS: 93.9 vs. 85.9%, respectively). Furthermore, presence of 
persistent CTCs 2 years after completion of chemotherapy in 
clinically disease-free patients predicted worse survival as well 
(33). In this context, one needs to keep in mind that CTCs 
represent a heterogenous population and that while systemic 
treatment may eradicate a large proportion of CTCs, tumor 
cells with enhanced resistant mechanisms may survive and 
lead to metastatic growth. To date, however, evidence regard-
ing clinical relevance of specific subtypes of persistent CTCs 
is limited.
Furthermore, Hall et  al. examined blood samples from 57 
patients with triple-negative BC after completion of neoadjuvant 
therapy and found a significant correlation between CTC pres-
ence and shorter relapse-free and overall survival (36). Others 
reported conflicting results in the neoadjuvant setting (14, 35, 
38). Several studies aimed at exploring the interaction between 
CTC dynamics and pathological changes in the primary tumor 
during chemotherapy. Pathological complete response has been 
shown to predict long-term survival and is being used as an 
endpoint in numerous clinical trials (39). However, changes 
in CTCs were not associated with tumor’s response to treat-
ment in most studies; in the neoadjuvant REMAGUS02 trial, 
neither presence of persistent CTCs after chemotherapy nor 
changes in CTC status correlated with pathological complete 
response (37). Riethdorf et  al. examined blood samples from 
213 BC patients before and 207 BC patients after neoadjuvant 
treatment in the GeparQuattro trial (34). While CTCs could 
be detected in 22% of patients before start of treatment, the 
positivity rate decreased to 11% after chemotherapy. However, 
no correlation between response to therapy and CTC dynamics 
could be found.
In the neoadjuvant setting, achievement of pathological com-
plete response is significantly linked to favorable survival. In case 
of adjuvant therapy, this simple tool for response monitoring is 
no longer available as systemic treatment is administered after 
surgery. In a study by Xenidis et al., 237 initially CTC-positive 
patients received either taxane-based or taxane-free adjuvant 
therapy (40). After a median follow-up of 71  months, patients 
treated with taxane-based regimen had longer DFS than those 
receiving taxane-free treatment. Positive effects on survival in 
the taxane-group were reflected by a shift toward CTC-negative 
status: 50% of taxane-treated patients turned CTC-negative 
compared to only 33% in the taxane-free arm.
Therapy Choices Based on  
CTCs in early BC
Treatment decisions in non-metastatic BC are based on the 
characteristics of the primary tumor without considering 
features of MRD, although the latter is the aim of any adjuvant 
strategy and molecular profile of MRD may differ from the 
primary tumor (41). For instance, we previously reported that 
71% of patients with ER-positive BC present with ER-negative 
DTCs in BM; the loss of hormone receptor positivity may 
contribute to development of endocrine resistance (42). With 
regard to another predictive marker, HER2, Riethdorf et  al. 
demonstrated that in 19% of patients with HER2-negative BC 
HER2-positive CTCs may be detected in PB (34). Similar results 
were reported with respect to DTCs in BM as well (26, 34, 43). 
According to current guidelines, patients with HER2-positive 
MRD but HER2-negative tumors are not eligible for anti-HER2-
targeted treatment since only histologically proven HER2 
status – either in the primary tumor or in a metastatic lesion 
– is taken into account. Whether this undertreatment results 
in worse survival and, consequently, whether these patients 
benefit from HER2-targeted therapy, remains to be clarified. 
Rack et al. showed that secondary adjuvant administration of 
trastuzumab eliminates HER2-positive DTCs from the BM of 
patients with HER2-negative BC (44). The ongoing TREAT 
CTC trial (NCT01548677) is the first liquid biopsy-based large 
trial evaluating the concept of targeting chemoresistant MRD 
(45). Patients with CTCs persisting beyond (neo)adjuvant 
chemotherapy are randomized between six cycles of trastu-
zumab intravenously every 3 weeks vs. observation. In this trial, 
HER2 status of the CTCs will be assessed, but the treatment is 
based on the presence of CTCs and not on their HER2 status. 
Apart from the patients’ characteristics of the pilot phase, this 
trial has not reported any results yet.
CiRCULATiNG TUMOR CeLLS iN 
MeTASTATiC BReAST CANCeR
Prognostic Significance of  
CTCs in Metastatic BC
A total of 40–80% of patients with metastatic BC present with 
CTCs in PB (Table 3). As demonstrated by Cristofanilli et al., CTC 
levels above the cutoff value of ≥5 cells/7.5 ml blood at the time of 
diagnosis are associated with impaired clinical outcome (46, 47). 
The prognostic value of the threshold of ≥5 CTCs/7.5 ml PB has 
been further validated by several studies and remains unchanged 
during the follow-up (37, 47–52). A recent pooled analysis on 
1944 metastatic BC patients demonstrated the influence of CTCs 
on progression-free and overall survival with the highest level of 
evidence (53).
Next to the prognostic role of CTC status, changes in CTC 
counts in course of treatment have been shown to reflect therapy 
response: in the analysis by Hayes et al., a decrease in CTC levels 
under the threshold of five cells in 7.5  ml PB predicted better 
PFS and OS (49). Furthermore, treatment efficacy assessed by 
CTC evaluation might be more suitable for therapy monitoring 
than standard radiological imaging (48). In a prospective trial by 
Budd et al., CTC persistence in metastatic BC patients predicted 
impaired clinical outcome despite radiological therapy response 
(48). In this context, a simple and non-invasive blood analysis 
for CTCs as a “liquid biopsy” represents an attractive tool allow-
ing a real-time monitoring of disease progression and therapy 
response.
Beyond CTC enumeration and monitoring of CTC levels 
during the therapy, characterization of these cells, especially 
with regard to hormone and HER2 status, has been addressed in 
TABLe 3 | Prognostic value of CTCs in metastatic breast cancer patients.
Reference Number of patients Method CTC positivity Association between CTCs and survival
Bidard et al. (53) 1944 CellSearch 47%a PFS, OS
Smerage et al. (54) 564 CellSearch 51%a PFS, OS
Wallwiener et al. (52) 486 CellSearch 42% PFS, OS
Giordano et al. (51) 517 CellSearch 40%a PFS, OS
Pierga et al. (55) 267 CellSearch 44%a PFS, OS
Müller et al. (56) 254 CellSearch AdnaTest CSS: 50%a AT: 40% CellSearch: OS AdnaTest: n.s.
Giuliano et al. (50) 235 CellSearch 40%a PFS, OS
Nakamura et al. (57) 107 CellSearch 37%a PFS
Liu et al. (58) 74 CellSearch n.s. PFS
Tewes et al. (59) 42 AdnaTest 52% OS
Bidard et al. (60) 37 Immunocytochemistry 41% OS
Nole et al. (61) 80 CellSearch 61% PFS
Hayes et al. (49) 177 CellSearch 54% PFS, OSb
Budd et al. (48) 138 CellSearch 43% OS
Cristofanilli et al. (47) 177 CellSearch 49% PFS, OS
PFS, progression-free survival; OS, overall survival.
a≥5 CTCs.
bAt any time during palliative treatment.
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several studies on metastatic BC. According to numerous trials, 
the phenotype and genotype of primary tumor, metastatic lesion, 
and CTCs often differ (62–66). Hypothetically, CTCs represent the 
dominant tumor cell population in metastatic disease; therefore, 
their expression profile may predict therapeutic response most 
adequately (67). As reported to date, targeted therapy guided by 
phenotype of CTCs is able to eliminate persistent tumor cells 
from PB and/or BM of BC patients (44, 68, 69). While prognostic 
relevance of CTC enumeration in the metastatic setting has been 
proven in large clinical trials, studies investigating the impact of 
specific phenotypes of CTCs on survival have yielded contradic-
tory results. Wallwiener et al. evaluated HER2 status on CTCs in 
107 metastatic BC patients starting a new line of therapy (65). The 
HER2 status of CTCs did not influence overall survival. However, 
patients with HER2-positive CTCs had significantly longer PFS 
than those with HER2-negative CTCs. In contrast, Hayashi et al. 
reported worse survival in patients with HER2-positive CTCs 
(70), and Beije et al. assessed ER and HER2 status on CTCs from 
154 MBC patients and reported that none correlated with clinical 
outcome (71).
Clinical significance of CTC phenotype (in particular, the 
HER2 status) for guiding treatment decisions and evaluating 
therapy response in metastatic BC is being currently investigated 
within the German DETECT trials (NCT01619111). Moreover, 
the possibility to provide an analysis of CTCs in metastatic BC 
on a DNA, RNA, and protein level including next-generation 
sequencing has been demonstrated by recent research (72, 73). 
CTC characterization on the molecular level might help to iden-
tify resistance mechanisms of tumor cells: a crucial step for the 
optimization of systemic treatment (67).
CTCs as a Therapy Monitoring  
Tool in Metastatic BC
While the prognostic relevance of CTC detection has been 
proven in large clinical trials, its clinical utility remains to be 
demonstrated (13, 47). Since CTC detection predicts impaired 
clinical outcome and CTC dynamics seem to reflect treatment 
response, a question has been raised, whether MBC patients 
can benefit from CTC-guided therapy decisions. The first large 
clinical trial to address this issue is the SWOG S0500 study 
(NCT00382018). In this randomized Phase III trial, metastatic 
BC patients with persistent high levels of CTCs after first cycle 
of initial chemotherapy (≥5/7.5 ml of blood) were randomized 
to switch the therapy or to maintain the current treatment until 
the clinical evidence of progression (54). While the strong 
prognostic power of CTCs has been confirmed by this study, 
treatment change based on CTC persistence did not improve 
progression-free survival or overall survival in these patients. 
The clinical outcome was poorest in patients with persistently 
elevated CTC levels, and these patients might represent a 
chemoresistant population that requires alternative treatment 
approaches (54). Furthermore, a currently ongoing study on 
therapy guidance based on CTC dynamics in metastatic BC is 
the CirCe01 by Institut Curie, France (NCT01349842). In this 
multicentre randomized Phase III study, therapy response in 
CTC-positive patients with disease progression after two lines of 
chemotherapy is being assessed by clinical tests and radiological 
imaging or by CTC enumeration. Patients without a significant 
decrease in CTC levels after first cycle of new chemotherapy will 
be switched to an alternative regime, which will also be evaluated 
by CTCs. First results of CirCe01 are expected in 2018 (74). Both 
studies attempt to demonstrate that patients with persistently 
elevated CTCs under cytotoxic treatment should be switched 
off this regimen early in order to avoid inefficient and toxic 
chemotherapies.
Therapy Choices Based on CTCs in 
Metastatic BC
The question whether the choice of systemic treatment in 
hormone receptor-positive HER2-negative metastatic BC 
patients might be driven by CTC levels has been raised by the 
STIC-CTC trial (NCT01710605, Institut Curie, France). In this 
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randomized Phase III trial, the treatment decision will be left 
at the discretion of the clinicians or according to the number 
of CTCs in PB: endocrine therapy in case of a CTC count <5 
CTCs/7.5  ml PB or chemotherapy in case of a CTC count 
≥5/7.5 ml PB.
The worldwide largest trial for therapy guidance according to 
the CTC status and/or CTC phenotype in metastatic BC patients 
is the DETECT study concept. In this multicenter study, women 
with HER2-negative metastatic disease and at least one HER2-
positive CTC are enrolled in the DETECT III trial (NCT01619111), 
and women with HER2-negative BC (hormone receptor-positive 
or triple-negative) and exclusively HER2-negative CTCs are 
eligible for the DETECT IV trial (NCT02035813). The recently 
initiated DETECT V/CHEVENDO trial (Chemo vs. Endo, 
NCT02344472) completes the DETECT study program with 
a clinical trial for HER2-positive hormone receptor-positive 
metastatic BC patients. In the DETECT III trial, patients are 
randomized to standard systemic treatment of physician’s 
choice ± additional therapy with lapatinib. In the DETECT IV 
trial, patients with hormone receptor-positive tumors are treated 
with endocrine therapy plus everolimus, as a study medication, 
whereas patients with hormone receptor-positive tumors and 
indication for chemotherapy as well as patients with triple-nega-
tive tumors are treated with eribulin. Metastatic BC patients with 
HER2-positive hormone receptor-positive tumors are treated 
with dual HER2-targeted therapy (pertuzumab/trastuzumab) 
either in combination with chemotherapy or endocrine therapy 
within the DETECT V/CHEVENDO trial. In DETECT III and 
DETECT IV, presence of CTCs is mandatory for study inclusion 
and changes in CTC levels during the treatment are evaluated by 
repeated blood sampling during the therapy. The accompany-
ing translational research projects of all DETECT studies try 
to generate additional knowledge of CTCs, their biology and 
their role in predicting treatment response using methods like 
single cell analysis, SNaP-Shot technology and next-generation 
sequencing. This may help to identify new treatment targets and 
provide more individualized therapy and finally further clarify 
the clinical value of CTCs in metastatic BC. Currently, ongoing 
trials on therapeutic utility of CTCs in metastatic BC are sum-
marized in Table 4.
CONCLUSiON
Evaluation of CTCs is one of the most promising biomarkers in 
solid tumors. In BC, presence of CTCs is an independent predic-
tor of poor clinical outcome in both early and metastatic setting. 
Numerous potential clinical applications have been proposed 
and are currently being investigated (Table 5). In case of early 
BC, the assessment of therapeutic targets is so far restricted to 
the primary tumor despite increasing evidence of significant 
discordances between primary tumor and MRD, especially with 
respect to hormone receptor and HER2 status. Since CTCs might 
reflect certain, hypothetically most aggressive, subpopulations 
of the tumor, molecular analysis of these cells and detection of 
their persistence might identify patients in need of additional or 
targeted treatment.
In metastatic disease, one of the most exciting possibilities is 
the concept of CTC-guided treatment. Two settings are currently 
TABLe 4 | Current studies on therapeutic utility of CTCs in metastatic breast cancer.
Trial Status Condition intervention Primary 
endpoint
SWOG S0500 NCT00382018  
(Phase III)
Active, not recruiting CTC persistence under 
chemotherapy
Treatment choice based on clinical and radiological 
criteria vs. CTC-guided treatment choice
OS
CirCe01 NCT01349842 (Phase III) Recruiting CTC persistence under 
chemotherapy
Treatment choice based on clinical and radiological 
criteria vs. CTC-guided treatment choice
OS
STIC-CTC NCT01710605 (Phase III) Recruiting HR+/HER2− MBC Clinicians choice vs. CTC-guided choice between 
chemotherapy and endocrine therapy
PFS
DETECT III NCT01619111 (Phase III) Recruiting HER2-negative metastatic BC 
with HER2-positive CTCs
Standard therapy ± lapatinib CTC clearance
DETECT IV NCT02035813 (Phase II) Recruiting HER2-negative metastatic BC 
with HER2-negative CTCs
Endocrine therapy + everolimus (DETECT IV a) or 
eribulin (DETECT IV b)
PFS
NCT01975142 (Phase II) Recruiting HER2-negative metastatic BC 
with HER2-positive CTCs
T-DM1 Tumor response 
rate
TABLe 5 | Potential future applications of CTC detection and 
characterization.
early BC Metastatic BC
• CTC detection might improve 
prognostication and help to identify 
patients in need of aggressive 
therapy and/or bisphosphonates
• CTC persistence might serve as 
stratifying parameter to select 
patients who benefit most from 
extended endocrine treatment
• Patients with CTC persistence 
beyond adjuvant chemotherapy 
might potentially benefit from 
secondary adjuvant treatment
• Evaluation of predictive markers 
on CTCs might serve as basis for 
treatment decisions: e.g., patients 
with HER2-negative primary tumor 
but HER2-positive CTCs might 
benefit from HER2-targeted therapy
• Detection of high CTC levels 
and thus worse prognosis might 
become a valuable information for 
improved care planning in palliative 
setting
• CTC detection after start of a 
new line of chemotherapy helps 
to predict response to treatment 
early; patients with high CTC 
levels might either be switched to 
another therapy approach (benefit 
so far not confirmed in trials) or 
to best supportive care to avoid 
unnecessary toxicity
• Evaluation of CTCs may serve as 
a liquid biopsy and thus render 
invasive biopsy of metastasis 
unnecessary; serial CTC 
measurements might provide 
continuous insight into current 
status of the disease
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be favored in such case. Second, a number of clinical trials aim 
at clarifying whether metastasized patients benefit from targeted 
therapy based on the molecular profile of CTCs rather than that 
of the primary tumor.
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